Achilles Therapeutics plc Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Achilles Therapeutics plc quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2022 to Q2 2024.
  • Achilles Therapeutics plc Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2024 was 40.4M shares, a 1.14% increase year-over-year.
  • Achilles Therapeutics plc annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 40M shares, a 2.13% increase from 2022.
  • Achilles Therapeutics plc annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 39.1M shares, a 36.6% increase from 2021.
  • Achilles Therapeutics plc annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 28.7M shares, a 2588% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 40.4M +456K +1.14% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-14
Q2 2023 39.9M +796K +2.03% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-14
Q2 2022 39.1M Apr 1, 2022 Jun 30, 2022 6-K 2023-08-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.